AU2019290722B2 - Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof - Google Patents
Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof Download PDFInfo
- Publication number
- AU2019290722B2 AU2019290722B2 AU2019290722A AU2019290722A AU2019290722B2 AU 2019290722 B2 AU2019290722 B2 AU 2019290722B2 AU 2019290722 A AU2019290722 A AU 2019290722A AU 2019290722 A AU2019290722 A AU 2019290722A AU 2019290722 B2 AU2019290722 B2 AU 2019290722B2
- Authority
- AU
- Australia
- Prior art keywords
- crystal form
- compound
- cancer
- disease
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018092194 | 2018-06-21 | ||
| CNPCT/CN2018/092194 | 2018-06-21 | ||
| PCT/CN2019/092239 WO2019242719A1 (zh) | 2018-06-21 | 2019-06-21 | 抑制cdk4/6活性化合物的晶型及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019290722A1 AU2019290722A1 (en) | 2021-01-28 |
| AU2019290722B2 true AU2019290722B2 (en) | 2023-12-21 |
Family
ID=68983152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019290722A Active AU2019290722B2 (en) | 2018-06-21 | 2019-06-21 | Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12043622B2 (enExample) |
| EP (1) | EP3812386A4 (enExample) |
| JP (1) | JP7430656B2 (enExample) |
| KR (1) | KR102768666B1 (enExample) |
| CN (2) | CN113861191B (enExample) |
| AU (1) | AU2019290722B2 (enExample) |
| BR (1) | BR112020026052A2 (enExample) |
| EA (1) | EA202190036A1 (enExample) |
| IL (1) | IL279579B2 (enExample) |
| MX (1) | MX2020013847A (enExample) |
| PH (1) | PH12020552236A1 (enExample) |
| SG (1) | SG11202012858QA (enExample) |
| TW (1) | TWI786303B (enExample) |
| WO (1) | WO2019242719A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI912499B (zh) * | 2021-03-24 | 2026-01-21 | 大陸商貝達藥業股份有限公司 | 藥物組合、包含其的試劑盒及其用途 |
| WO2023131179A1 (zh) * | 2022-01-05 | 2023-07-13 | 贝达药业股份有限公司 | 苯并咪唑衍生物或其盐在治疗白血病中的用途 |
| CN115872923B (zh) * | 2022-12-29 | 2023-04-28 | 成都泰和伟业生物科技有限公司 | 一种化合物及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016173505A1 (en) * | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016015604A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| CN104592251B (zh) * | 2015-01-23 | 2019-10-01 | 上海复星医药产业发展有限公司 | 4-(稠杂环取代氨基)-1h-吡唑-3-甲酰胺类化合物及其用途 |
| WO2017005900A1 (en) * | 2015-07-08 | 2017-01-12 | F. Hoffmann-La Roche Ag | ARYL SULTAM DERIVATIVES AS RORc MODULATORS |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| WO2017102796A1 (en) * | 2015-12-16 | 2017-06-22 | F. Hoffmann-La Roche Ag | HETEROARYL AMIDE SULTAM DERIVATIVES AS RORc MODULATORS |
| TWI646094B (zh) * | 2016-06-01 | 2019-01-01 | 大陸商貝達藥業股份有限公司 | Crystal form of inhibitory protein kinase active compound and application thereof |
| KR102543603B1 (ko) * | 2016-12-22 | 2023-06-14 | 베타 파머수티컬 컴퍼니 리미티드 | 벤조이미다졸 유도체, 제조 방법 및 그것의 용도 |
| US11351170B2 (en) * | 2017-08-15 | 2022-06-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Substituted pyrimidines as CDK4/6 inhibitors |
-
2019
- 2019-06-21 IL IL279579A patent/IL279579B2/en unknown
- 2019-06-21 CN CN202111208432.8A patent/CN113861191B/zh active Active
- 2019-06-21 MX MX2020013847A patent/MX2020013847A/es unknown
- 2019-06-21 BR BR112020026052-5A patent/BR112020026052A2/pt unknown
- 2019-06-21 KR KR1020217001384A patent/KR102768666B1/ko active Active
- 2019-06-21 TW TW108121799A patent/TWI786303B/zh active
- 2019-06-21 EP EP19822566.6A patent/EP3812386A4/en active Pending
- 2019-06-21 US US17/254,097 patent/US12043622B2/en active Active
- 2019-06-21 JP JP2020571503A patent/JP7430656B2/ja active Active
- 2019-06-21 WO PCT/CN2019/092239 patent/WO2019242719A1/zh not_active Ceased
- 2019-06-21 CN CN201980037275.3A patent/CN112424202B/zh active Active
- 2019-06-21 EA EA202190036A patent/EA202190036A1/ru unknown
- 2019-06-21 SG SG11202012858QA patent/SG11202012858QA/en unknown
- 2019-06-21 AU AU2019290722A patent/AU2019290722B2/en active Active
-
2020
- 2020-12-21 PH PH12020552236A patent/PH12020552236A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016173505A1 (en) * | 2015-04-28 | 2016-11-03 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019242719A1 (zh) | 2019-12-26 |
| CN112424202A (zh) | 2021-02-26 |
| US12043622B2 (en) | 2024-07-23 |
| KR20210024004A (ko) | 2021-03-04 |
| EA202190036A1 (ru) | 2021-03-24 |
| CA3104365A1 (en) | 2019-12-26 |
| BR112020026052A2 (pt) | 2021-03-23 |
| TW202016114A (zh) | 2020-05-01 |
| JP7430656B2 (ja) | 2024-02-13 |
| AU2019290722A1 (en) | 2021-01-28 |
| CN113861191A (zh) | 2021-12-31 |
| IL279579B (en) | 2022-10-01 |
| IL279579A (en) | 2021-03-01 |
| SG11202012858QA (en) | 2021-02-25 |
| EP3812386A4 (en) | 2022-03-30 |
| US20210261546A1 (en) | 2021-08-26 |
| IL279579B2 (en) | 2023-02-01 |
| KR102768666B1 (ko) | 2025-02-17 |
| MX2020013847A (es) | 2021-04-28 |
| TWI786303B (zh) | 2022-12-11 |
| CN112424202B (zh) | 2021-09-17 |
| CN113861191B (zh) | 2023-09-19 |
| PH12020552236A1 (en) | 2021-06-28 |
| JP2021529175A (ja) | 2021-10-28 |
| EP3812386A1 (en) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7383652B2 (ja) | Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用 | |
| WO2023116895A1 (zh) | Kras抑制剂的多晶型物及其制备方法和用途 | |
| CN109689641B (zh) | 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 | |
| JP2019518776A (ja) | Ｅｇｆｒ阻害剤としてのアニリンピリミジン化合物の結晶 | |
| US12043622B2 (en) | Crystal form of compound for inhibiting the activity of CDK4/6 and use thereof | |
| CN109593102B (zh) | 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型 | |
| CN121443610A (zh) | 一种plk1激酶抑制剂的盐型、晶型及其制备方法和应用 | |
| CA3104365C (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| CN113840605B (zh) | N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺盐酸盐的结晶形式及其用途 | |
| CN104119321B (zh) | 二氢吲哚酮衍生物的二马来酸盐及其多晶型物 | |
| CN108299419B (zh) | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 | |
| EA043251B1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
| CN107663207B (zh) | 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法 | |
| CN112004809A (zh) | 作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物 | |
| HK40037648A (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| HK40037648B (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| CN112654623B (zh) | 新型氮杂三环类化合物的盐型、晶型及其用途 | |
| TW202342041A (zh) | 一種藥物組合物及所含活性成分化合物的製備方法 | |
| WO2026021534A1 (zh) | 一种嘧啶类衍生物的固体形式及其制备方法和应用 | |
| WO2021249450A1 (zh) | 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途 | |
| CN120383595A (zh) | 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物 | |
| CN120289432A (zh) | 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途 | |
| CN121816346A (zh) | 含氮杂环类衍生物抑制剂的盐型、晶型及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |